Effect of fusaric acid in Parkinson's disease.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002214:Capsules; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010848:Picolinic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos
D000978:Antiparkinson Agents; D002214:Capsules; D010848:Picolinic Acids; D010919:Placebos; D004295:Dihydroxyphenylalanine